Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo ...

"Our team is pleased to report that SP-26 met all expectations in this preclinical study,” said Eric Weisblum, CEO of Silo Pharma. "We believe these results support the advancement of SP-26 as a ...